1
|
Visca P, Seifert H and Towner KJ:
Acinetobacter infection - an emerging threat to human health. IUBMB
Life. 63:1048–1054. 2011. View
Article : Google Scholar : PubMed/NCBI
|
2
|
Munoz-Price LS and Weinstein RA:
Acinetobacter infection. N Engl J Med. 358:1271–1281. 2008.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Dent LL, Marshall DR, Pratap S and Hulette
RB: Multidrug resistant Acinetobacter baumannii: A descriptive
study in a city hospital. BMC Infect Dis. 10:1962010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Principe L, D'Arezzo S, Capone A,
Petrosillo N and Visca P: In vitro activity of tigecycline in
combination with various antimicrobials against multidrug resistant
Acinetobacter baumannii. Ann Clin Microbiol Antimicrob.
8:182009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Lim TP, Tan TY, Lee W, Sasikala S, Tan TT,
Hsu LY and Kwa AL: In-vitro activity of polymyxin B, rifampicin,
tigecycline alone and in combination against carbapenem-resistant
Acinetobacter baumannii in Singapore. PLoS One.
6:e184852011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Weng XB and Mi ZH: Phylogenetic analysis
on pandrug-resistant Acinetobacter baumannii strains.
Zhonghua Liu Xing Bing Xue Za Zhi. 32:948–949. 2011.(In Chinese).
PubMed/NCBI
|
7
|
Zhao WS, Liu GY, Mi ZH and Zhang F:
Coexistence of blaOXA-23 with armA and novel gyrA mutation in a
pandrug-resistant Acinetobacter baumannii isolate from the
blood of a patient with haematological disease in China. J Hosp
Infect. 77:278–279. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Wen Y, Ouyang Z, Yu Y, Zhou X, Pei Y,
Devreese B, Higgins PG and Zheng F: Mechanistic insight into how
multidrug resistant Acinetobacter baumannii response
regulator AdeR recognizes an intercistronic region. Nucleic Acids
Res. 45:9773–9787. 2017. View Article : Google Scholar : PubMed/NCBI
|
9
|
Yang H, Huang L, Barnie PA, Su Z, Mi Z,
Chen J, Aparna V, Kumar D and Xu H: Characterization and
distribution of drug resistance associated β-lactamase, membrane
porin and efflux pump genes in MDR A. Baumannii isolated from
Zhenjiang, China. Int J Clin Exp Med. 8:15393–15402.
2015.PubMed/NCBI
|
10
|
Jiang W, Liu H, Zhong M, Yang YC, Xiao DW
and Huang WF: Study on the resistant genes to carbapenems and
epidemiological characterization of multidrug-resistant
Acinetobacter baumannii isolates. Microb Drug Resist.
19:117–123. 2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Ramirez MS and Tolmasky ME: Aminoglycoside
modifying enzymes. Drug Resist Updat. 13:151–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
12
|
Petersen A, Guardabassi L, Dalsgaard A and
Olsen JE: Class I integrons containing a dhfrl trimethoprim
resistance gene cassette in aquatic Acinetobacter spp. FEMS
Microbiol Lett. 182:73–76. 2000. View Article : Google Scholar : PubMed/NCBI
|
13
|
Azizi O, Shakibaie MR, Badmasti F,
Modarresi F, Ramazanzadeh R, Mansouri S and Shahcheraghi F: Class 1
integrons in non-clonal multidrug-resistant Acinetobacter
baumannii from Iran, description of the new blaIMP-55 allele in
In1243. J Med Microbiol. 65:928–936. 2016. View Article : Google Scholar : PubMed/NCBI
|
14
|
Tada T, Miyoshi-Akiyama T, Kato Y,
Ohmagari N, Takeshita N, Hung NV, Phuong DM, Thu TA, Binh NG, Anh
NQ, et al: Emergence of 16S rRNA methylase-producing
Acinetobacter baumannii and Pseudomonas aeruginosa
isolates in hospitals in Vietnam. BMC Infect Dis. 13:2512013.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Lee JK, Lee YS, Park YK and Kim BS:
Mutations in the gyrA and parC genes in ciprofloxacin-resistant
clinical isolates of Acinetobacter baumannii in Korea. Microbiol
Immunol. 49:647–653. 2005. View Article : Google Scholar : PubMed/NCBI
|
16
|
American Thoracic Society, . Infectious
Diseases Society of America: Guidelines for the management of
adults with hospital-acquired, ventilator-associated, and
healthcare-associated pneumonia. Am J Respir Crit Care Med.
171:388–416. 2005. View Article : Google Scholar : PubMed/NCBI
|
17
|
Clinical and Laboratory Standards
Institute: Performance standards for antimicrobial susceptibility
testing: Twenty-second informational supplement M100-S21. CLSI.
31:64–65. 2011.
|
18
|
Zhang T, Wang M, Xie Y, Li X, Dong Z, Liu
Y, Wang L, Yang M, Song H, Cao H and Cao W: Active efflux pump adeB
is involved in multidrug resistance of Acinetobacter
baumannii induced by antibacterial agents. Exp Ther Med.
13:1538–1546. 2017. View Article : Google Scholar : PubMed/NCBI
|
19
|
Benson DA, Karsch-Mizrachi I, Lipman DJ,
Ostell J and Wheeler DL: GenBank. Nucleic Acids Res. 33:(Database
Issue). D34–D38. 2005. View Article : Google Scholar : PubMed/NCBI
|
20
|
Daoud Z, Mansour N and Masri K:
Synergistic combination of carbapenems and colistin against P.
aeruginosa and A. baumannii. Open J Med Microbiol.
3:253–258. 2013. View Article : Google Scholar
|
21
|
Huang J, Chen EZ, Qu HP, Mao EQ, Zhu ZG,
Ni YX, Han LZ and Tang YQ: Sources of multidrug-resistant
Acinetobacter baumannii and its role in respiratory tract
colonization and nosocomial pneumonia in intensive care unit
patients. Chin Med J (Engl). 126:1826–1831. 2013.PubMed/NCBI
|
22
|
Xu T, Xia W, Rong G, Pan S, Huang P and Gu
B: A 4-year surveillance of antimicrobial resistance patterns of
Acinetobacter baumanni in a university-affiliated hospital
in China. J Thorac Dis. 5:506–512. 2013.PubMed/NCBI
|
23
|
Koeleman JG, Stoof J, Biesmans DJ,
Savelkoul PH and Vandenbroucke-Grauls CM: Comparison of amplified
ribosomal DNA restriction analysis, random amplified polymorphic
DNA analysis, and amplified fragment length polymorphism
fingerprinting for identification of Acinetobacter genomic
species and typing of Acinetobacter baumannii. J Clin
Microbiol. 36:2522–2529. 1998.PubMed/NCBI
|
24
|
Fontana C, Favaro M, Minelli S, Bossa MC,
Testore GP, Leonardis F, Natoli S and Favalli C: Acinetobacter
baumannii in intensive care unit: A novel system to study
clonal relationship among the isolates. BMC Infect Dis. 8:792008.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Niranjan DK, Singh NP, Manchanda V, Rai S
and Kaur IR: Multiple carbapenem hydrolyzing genes in clinical
isolates of Acinetobacter baumannii. Indian J Med Microbiol.
31:237–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Feizabadi MM, Fathollahzadeh B,
Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, Soroush
S and Mohammadi-Yegane S: Antimicrobial susceptibility patterns and
distribution of blaOXA genes among Acinetobacter spp.
Isolated from patients at Tehran hospitals. Jpn J Infect Dis.
61:274–278. 2008.PubMed/NCBI
|
27
|
Thapa B, Tribuddharat C, Srifuengfung S
and Dhiraputra C: High prevalence of bla(OXA)-23 in oligoclonal
carbapenem-resistant Acinetobacter baumannii from Siriraj
Hospital, Mahidol University, Bangkok, Thailand. Southeast Asian J
Trop Med Public Health. 41:625–635. 2010.PubMed/NCBI
|
28
|
Chen Z, Liu W, Zhang Y, Li Y, Jian Z, Deng
H, Zou M and Liu Y: Molecular epidemiology of carbapenem-resistant
Acinetobacter spp. from XiangYa Hospital, in Hunan Province,
China. J Basic Microbiol. 53:121–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
29
|
Sung JY, Kwon KC, Cho HH and Koo SH:
Antimicrobial resistance determinants in imipenem-nonsusceptible
Acinetobacter calcoaceticus-baumannii complex isolated in
Daejeon, Korea. Korean J Lab Med. 31:265–270. 2011. View Article : Google Scholar : PubMed/NCBI
|
30
|
Peymani A, Farajnia S, Nahaei MR, Sohrabi
N, Abbasi L, Ansarin K and Azhari F: Prevalence of class 1 integron
among multidrug-resistant Acinetobacter baumannii in Tabriz,
northwest of Iran. Pol J Microbiol. 61:57–60. 2012.PubMed/NCBI
|
31
|
Farajnia S, Azhari F, Alikhani MY,
Hosseini MK, Peymani A and Sohrabi N: Prevalence of PER and VEB
type extended spectrum betalactamases among multidrug resistant
acinetobacter baumannii Isolates in North-West of Iran. Iran J
Basic Med Sci. 16:751–755. 2013.PubMed/NCBI
|
32
|
Yoon EJ, Courvalin P and Grillot-Courvalin
C: RND-type efflux pumps in multidrug-resistant clinical isolates
of Acinetobacter baumannii: Major role for AdeABC
overexpression and AdeRS mutations. Antimicrob Agents Chemother.
57:2989–2995. 2013. View Article : Google Scholar : PubMed/NCBI
|
33
|
Jones RN, Barry AL, Packer RR, Gregory WW
and Thornsberry C: In vitro antimicrobial spectrum, occurrence of
synergy, and recommendations for dilution susceptibility testing
concentrations of the cefoperazone-sulbactam combination. J Clin
Microbiol. 25:1725–1729. 1987.PubMed/NCBI
|
34
|
Barry AL and Jones RN: Criteria for disk
susceptibility tests and quality control guidelines for the
cefoperazone-sulbactam combination. J Clin Microbiol. 26:13–17.
1988.PubMed/NCBI
|
35
|
Pei G, Mao Y and Sun Y: In vitro activity
of minocycline alone and in combination with cefoperazone-sulbactam
against carbapenem-resistant Acinetobacter baumannii. Microb Drug
Resist. 18:574–577. 2012. View Article : Google Scholar : PubMed/NCBI
|
36
|
Deveci A, Coban AY, Acicbe O, Tanyel E,
Yaman G and Durupinar B: In vitro effects of sulbactam combinations
with different antibiotic groups against clinical Acinetobacter
baumannii isolates. J Chemother. 24:247–252. 2012. View Article : Google Scholar : PubMed/NCBI
|